A recently formed family office has invested in a listed biotech group developing treatments for Parkinson’s disease. The Canadian family office is also building a portfolio of real estate holdings in New York City.
Subscribe
You will need a Premium+ Subscription to read this article.
Exclusive news, analysis and research on global family enterprise and private investment offices
Already have an account? Sign in
Already have an account? Sign in
You've reached the end.
Continue reading free articles by registering as a Member.
Or choose a Premium Plan.
Already have an account? Sign in